TICEBA founds subsidiary RHEACELL.

TICEBA - Company - RHEACELL GmbH & Co. KG - Picture 01TICEBA - Company - RHEACELL GmbH & Co. KG - Picture 02


RHEACELL is dedicated to the development of human pharmaceuticals based on ABCB5-positive mesenchymal skin stem cells. For selected indications RHEACELL strives for improvement of quality of life as well as abatement and healing of ailments of patients.

TICEBA contributes its established know-how as well as its qualified employees to the success of the development of pharmaceuticals of RHEACELL.

Please click HERE for more information on RHEACELL.

TICEBA - Company - RHEACELL GmbH & Co. KG - Picture 03

Clinical Trials

We are now also recruiting patients for further clinical studies in phase I/IIa with allogeneic ABCB5-positive (ABCB5+) mesenchymal stem cells for the following indications: chronic venous ulcers (CVU), diabetic foot ulcers (DFU) and peripheral arterial occlusive disease (PAOD). For more information click HERE.


Besides the authorization to manufacture a human medicinal product in accordance with § 13 (1) of the German Medicinal Products Act (AMG) for autologous mesenchymal stem cells, TICEBA is also authorized to manufacture a medicinal product for allogeneic mesenchymal as well as allogeneic limbal ABCB5 + stem cells following a recent extension. For more information click HERE.

The Story of Stem Cells

Review our category "The Story of Stem Cells" with the newest topic "Stem cells in wound healing" HERE.